U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol drug Vytorin after a study showed it was no better than a generic in preventing the build-up of fatty plaque.The Food and Drug Administration said it had not yet received a final report on the study, called ENHANCE. The agency's review of Vytorin will take about six months after final results are received, the FDA said.
More at Reuters
No comments:
Post a Comment